Omeros (OMER)
(Delayed Data from NSDQ)
$3.91 USD
+0.14 (3.58%)
Updated Sep 24, 2024 03:54 PM ET
After-Market: $3.89 -0.02 (-0.38%) 4:50 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 1 - 20 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
3Q21 Financials; Top-Line In-Line, Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Complete Response Letter Deals Harsh Blow; Reducing PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Emerging Pharmaceuticals - Dropping Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Approval Delay Likely; Lowering PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Another Narsoplimab PDUFA Delay Creates Uncertainty Ahead; D/g to UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
OMS721 Approval Decision Next Month; Healthy OMIDRIA Sales; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Q2: OMIDRIA Sales Climb with ASC Growth; Focus on Narsoplimab October 17 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMS906 Progress; Narsoplimab Approval Delay Looks Minor; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Solid Top-Line Beat, Bottom-Line In-Line for 1Q21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Q1: Narsoplimab/HSCT-TMA Launch Preparations Underway Ahead of July 17 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Approval Decision Near-Term; Modulating PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q4/FY20: Pipeline Progress; Focus Remains on Narsoplimab/TA-TMA PDUFA in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab/HSCT-TMA PDUFA Set for July 17, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L